Related Experiment Video
Updated: May 27, 2026
Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
Published on: July 25, 2011
Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications
Parsa Alijanizadeh1,2, Mahshid Shahmoradi1,3, Amirhossein Kamroo4,5,6,7
1Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer that evades immune surveillance by impairing the NKG2D receptor on natural killer (NK) cells and cytotoxic T lymphocytes. NKG2D recognizes stress-induced ligands (e.g., MICA, MICB, ULBPs) on tumor cells, but HNSCC tumors counteract this by shedding soluble ligands and secreting immunosuppressive cytokines like TGF-β1, reducing NKG2D expression and function. This review explores therapeutic strategies targeting the NKG2D axis to enhance HNSCC treatment. Cytokine therapies, such as IL-2 or IL-15, boost NKG2D-dependent NK cell activation. Monoclonal antibodies targeting MICA/B or ULBPs prevent ligand shedding and induce antibody-dependent cellular cytotoxicity (ADCC). Engineered cell therapies, including NKG2D-based chimeric antigen receptor (CAR)-T and CAR-NK cells, show potent preclinical efficacy against HNSCC. Combining these approaches with EGFR-targeted antibodies (e.g., cetuximab) or checkpoint inhibitors enhances NKG2D-mediated immunity. Despite promising results, challenges persist, including heterogeneous ligand expression, persistent shedding, and the immunosuppressive tumor microenvironment, which limit clinical efficacy. Future directions include multimodal strategies like bispecific NK-cell engagers and integration with chemoradiotherapy to overcome these barriers. By restoring NKG2D-driven immunity, these therapies hold potential to improve outcomes for HNSCC patients, though further research is needed to optimize their clinical translation.
Insights
Head and neck squamous cell carcinoma (HNSCC) impairs immune cells via the NKG2D receptor. Therapies targeting this axis, including cytokines and engineered cells, show promise for HNSCC treatment.
Area of Science:
- Immunology
- Oncology
- Cancer Therapy
Background:
- Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer.
- HNSCC evades immune surveillance by downregulating the NKG2D receptor on immune cells.
- Tumors shed NKG2D ligands and secrete immunosuppressive cytokines, hindering anti-tumor immunity.
Purpose of the Study:
- To review therapeutic strategies targeting the NKG2D axis for HNSCC treatment.
- To explore novel approaches to restore NKG2D-mediated anti-tumor immunity.
- To identify challenges and future directions in NKG2D-targeted HNSCC therapy.
Main Methods:
- Review of existing literature on NKG2D axis modulation in HNSCC.
- Analysis of cytokine therapies (IL-2, IL-15) enhancing NKG2D function.
- Evaluation of monoclonal antibodies and engineered cell therapies (CAR-T, CAR-NK) targeting NKG2D ligands.
- Assessment of combination strategies with EGFR inhibitors and checkpoint inhibitors.
Main Results:
- Cytokine therapies boost NKG2D-dependent NK cell activation.
- Monoclonal antibodies targeting NKG2D ligands prevent shedding and induce ADCC.
- NKG2D-based CAR-T and CAR-NK cells demonstrate preclinical efficacy against HNSCC.
- Combination therapies enhance NKG2D-mediated immunity.
Conclusions:
- Targeting the NKG2D axis offers a promising strategy to enhance HNSCC treatment.
- Challenges include ligand heterogeneity, shedding, and the immunosuppressive tumor microenvironment.
- Multimodal strategies and integration with standard therapies are crucial for clinical translation.
